Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday a settlement agreement with U.K.-based Hikma Pharmaceuticals ...

HC Wainwright reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $200.00 price ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S.

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...

Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $132 and keeps an Outperform rating on the shares. The firm ...

Axsome Therapeutics, a biopharmaceutical company targeting central nervous system (CNS) disorders, develops novel therapies for depression, narcolepsy, and other CNS conditions. Its current ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Axsome Therapeutics AXSM incurred an adjusted loss of 96 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a ...

Axsome Therapeutics, Inc. NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...